Published in AIDS Weekly, August 24th, 1998
The CDC researchers found that prior rifabutin therapy as Mycobacterium avium complex (MAC)-prophylaxis could explain part, but not all, of the increase in rifampin mono-resistance among HIV positive tuberculosis patients.
"Although prior tuberculosis and rifabutin use were identified as risk factors for mono-rifampin resistance, these factors could not explain the majority of mono-rifampin resistant cases in this study," Renee Ridzon and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.